All In Biotech

Drug Trial Radar · NCT05662319

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

91

Actual

Start

Feb 1, 2023

Primary completion

Mar 25, 2027

Study completion Jan 25, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include: * A screening period up to approximately 60 days, * A standard of care (SOC) period of approximately 6 study months (24 weeks), * A fitusiran treatment period of approximately 36 study months (144 weeks), * An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery. The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study

Conditions

  • Hemophilia

Interventions

  • FitusiranDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)

  • Clotting factor concentrates (CFC) or bypassing agents (BPA)Drug

    * Coagulation factor VIII (ATC code: B02BD02) * Coagulation factor IX (ATC code: B02BD04) * Coagulation factor VIIa (ATC code: B02BD08) * Factor VIII inhibitor bypassing activity (ATC code: B02BD03) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)

  • Antithrombin concentrate (ATIIIC)Drug

    Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized bleeding rate (ABR) in the fitusiran primary efficacy periodTime frame: Day 169 to Day 505 (since the first dose of fitusiran)

Locations

50 sites in 17 countries. Site status is shown where the registry gives one.

  • Center for Inherited Blood Disorders (CIBD) Site Number : 8400012

    Orange, California

  • M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016

    Minneapolis, Minnesota

  • Hackensack University Site Number : 8400009

    Hackensack, New Jersey

  • Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015

    New Hyde Park, New York

  • University Hospitals of Cleveland Site Number : 8400001

    Cleveland, Ohio

  • UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017

    Pittsburgh, Pennsylvania

  • Children's Medical Center Dallas- Site Number : 8400018

    Dallas, Texas

  • Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002

    Houston, Texas

  • Investigational Site Number : 1240001

    Hamilton, Ontario, Canada

  • Investigational Site Number : 1240002

    Hamilton, Ontario, Canada

  • Investigational Site Number : 1240004

    Toronto, Ontario, Canada

  • Investigational Site Number : 1560003

    Beijing, China

  • Investigational Site Number : 1560001

    Guangzhou, China

  • Investigational Site Number : 1560002

    Jinan, China

  • Investigational Site Number : 2500003

    Le Kremlin-Bicêtre, France

  • Investigational Site Number : 2500002

    Lille, France

  • Investigational Site Number : 2500001

    Paris, France

  • Investigational Site Number : 2760001

    Berlin, Germany

  • Investigational Site Number : 2760002

    Hamburg, Germany

  • Investigational Site Number : 3000001

    Athens, Greece

  • Investigational Site Number : 3000002

    Athens, Greece

  • Investigational Site Number : 3560004

    Bangalore, India

  • Investigational Site Number : 3560007

    Bhubaneswar, India

  • Investigational Site Number : 3560001

    Pune-411011, India

  • Investigational Site Number : 3560006

    Punjab, India

  • Investigational Site Number : 3560003

    Vellore, India

  • Investigational Site Number : 3800001

    Milan, Italy

  • Investigational Site Number : 3800003

    Rozzano, Milano, Italy

  • Investigational Site Number : 3920003

    Nagoya, Aichi-ken, Japan

  • Investigational Site Number : 3920001

    Kashihara-shi, Nara, Japan

  • Investigational Site Number : 3920002

    Saitama-shi, Saitama, Japan

  • Investigational Site Number : 4840004

    Chihuahua City, Mexico

  • Investigational Site Number : 4840001

    Veracruz, Mexico

  • Investigational Site Number : 4840002

    Monterrey, Nuevo León, Mexico

  • Investigational Site Number : 6160002

    Krakow, Lesser Poland Voivodeship, Poland

  • Investigational Site Number : 6160004

    Lodz, Lódzkie, Poland

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6820002

    Jeddah, Saudi Arabia

  • Investigational Site Number : 7100003

    Johannesburg, South Africa

  • Investigational Site Number : 7100001

    Parktown, South Africa

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.